Principia Wealth Advisory’s BioMarin Pharmaceuticals BMRN Stock Holding History

Principia Wealth Advisory’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$458	Sell	8 -2	-20%	-$110	﹤0.01%	907
2026 Q1	$565	Buy	10 +1	+11%	+$58	﹤0.01%	837
2025 Q4	$535	Buy	9 +3	+50%	+$163	﹤0.01%	807
2025 Q3	$325	Hold	6	–	–	﹤0.01%	848
2025 Q2	$330	Sell	6 -4	-40%	-$236	﹤0.01%	834
2025 Q1	$594	Buy	10 +4	+67%	+$269	﹤0.01%	531
2024 Q4	$394	Buy	+6	New	+$402	﹤0.01%	609

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Principia Wealth Advisory's BMRN Position: Q2 2026 in Review

Principia Wealth Advisory reduced its BioMarin Pharmaceuticals (BMRN) stake by 20% in Q2 2026, selling an estimated $110 and leaving 8 shares worth $458. The position accounts for ﹤0.01% of the portfolio, ranked #907.

Principia Wealth Advisory first reported a position in BMRN in Q4 2024 and has held it in 7 quarters since. The position peaked at $594 in Q1 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Principia Wealth Advisory held 8 shares of BioMarin Pharmaceuticals worth $458 as of Q2 2026.
Principia Wealth Advisory sold 2 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $110.
BioMarin Pharmaceuticals made up ﹤0.01% of Principia Wealth Advisory's portfolio in Q2 2026, its #907 holding.
Principia Wealth Advisory first reported a position in BioMarin Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
Principia Wealth Advisory's BioMarin Pharmaceuticals position peaked at $594 in Q1 2025.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Principia Wealth Advisory's 13F filing for Q2 2026, filed 26 Aug 2026.